A phase I, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ISIS 325568 administered to healthy volunteers

Trial Profile

A phase I, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ISIS 325568 administered to healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs ISIS 325568 (Primary) ; ISIS 325568 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA-2010), according to a Isis Pharmaceuticals media release.
    • 18 Aug 2008 Planned end date changed from 1 Jul 2008 to 1 Jun 2008, according to Clinicaltrials.gov.
    • 18 Aug 2008 Status changed from active, no longer recruiting to completed, reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top